title: Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.
abstract: Bisphosphonates are effective in the prevention and treatment of bone disease in multiple myeloma (MM). Osteonecrosis of the jaw is Increasingly recognized as a serious complication of long-term bisphosphonate therapy. Issues such as the choice of bisphosphonate and duration of therapy have become the subject of intense debate given patient safety concerns. We reviewed available data concerning the use of bisphosphonates in MM. Guidelines for the use of bisphosphonates in MM were developed by a multidisciplinary panel consisting of hematologists, dental specialists, and nurses specializing in the treatment of MM. We conclude that intravenous pamidronate and intravenous zoledronic acid are equally effective and superior to placebo in reducing skeletal complications. Pamidronate is favored over zoledronic acid until more data are available on the risk of complications (osteonecrosis of the jaw). We recommend discontinuing bisphosphonates after 2 years of therapy for patients who achieve complete response and/or plateau phase. For patients whose disease is active, who have not achieved a response, or who have threatening bone disease beyond 2 years, therapy can be decreased to every 3 months. These guidelines were developed in the Interest of patient safety and will be reexamined as new data emerge regarding risks and benefits.
authors.affiliation: Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA. lacy.martha@mayo.edu
authors.forename: Martha Q
authors.initials: MQ
authors.lastname: Lacy
authors.forename: Angela
authors.initials: A
authors.lastname: Dispenzieri
authors.forename: Morie A
authors.initials: MA
authors.lastname: Gertz
authors.forename: Philip R
authors.initials: PR
authors.lastname: Greipp
authors.forename: Kimberly L
authors.initials: KL
authors.lastname: Gollbach
authors.forename: Suzanne R
authors.initials: SR
authors.lastname: Hayman
authors.forename: Shaji
authors.initials: S
authors.lastname: Kumar
authors.forename: John A
authors.initials: JA
authors.lastname: Lust
authors.forename: S Vincent
authors.initials: SV
authors.lastname: Rajkumar
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Russell
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Witzig
authors.forename: Steven R
authors.initials: SR
authors.lastname: Zeldenrust
authors.forename: David
authors.initials: D
authors.lastname: Dingli
authors.forename: P Lief
authors.initials: PL
authors.lastname: Bergsagel
authors.forename: Rafael
authors.initials: R
authors.lastname: Fonseca
authors.forename: Craig B
authors.initials: CB
authors.lastname: Reeder
authors.forename: A Keith
authors.initials: AK
authors.lastname: Stewart
authors.forename: Vivek
authors.initials: V
authors.lastname: Roy
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Dalton
authors.forename: Alan B
authors.initials: AB
authors.lastname: Carr
authors.forename: Deepak
authors.initials: D
authors.lastname: Kademani
authors.forename: Eugene E
authors.initials: EE
authors.lastname: Keller
authors.forename: Christopher F
authors.initials: CF
authors.lastname: Viozzi
authors.forename: Robert A
authors.initials: RA
authors.lastname: Kyle
mesh_terms: D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D008910:Minnesota; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy*; D010024:Osteoporosis / Q000209:etiology / Q000517:prevention & control*; D000077268:Pamidronate; D017410:Practice Guidelines as Topic; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D000077268:Pamidronate